Frequent mutation of PI3K/AKT/mTOR signaling pathway genes in human cancers has stimulated large investments in targeted drugs but clinical successes are rare. As a result, many cancers with high PI3K pathway activity, such as triple-negative breast cancer (TNBC), are treated primarily with chemotherapy. By systematically analyzing responses of TNBC cells to a diverse collection of PI3K pathway inhibitors, we find that one drug, Torin2, is unusually effective because it inhibits both mTOR and other PI3K-like kinases (PIKKs). In contrast to mTOR-selective inhibitors, Torin2 exploits dependencies on several kinases for S-phase progression and cell-cycle checkpoints, thereby causing accumulation of single-stranded DNA and death by replication catastrophe or mitotic failure. Thus, Torin2 and its chemical analogs represent a mechanistically distinct class of PI3K pathway inhibitors that are uniquely cytotoxic to TNBC cells. This insight could be translated therapeutically by further developing Torin2 analogs or combinations of existing mTOR and PIKK inhibitors.
Keywords: ATR/Chk1; PI3K/AKT/mTOR; Torin2; cell cycle; mitotic catastrophe; polypharmacology; replication catastrophe; replication stress; small molecule drugs; triple-negative breast cancer.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.Cancer Res. 2013 Apr 15;73(8):2574-86. doi: 10.1158/0008-5472.CAN-12-1702. Epub 2013 Feb 22. Cancer Res. 2013. PMID: 23436801 Free PMC article.
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Breast Cancer Res Treat. 2018 Jun;169(3):397-406. doi: 10.1007/s10549-018-4697-y. Epub 2018 Feb 7. Breast Cancer Res Treat. 2018. PMID: 29417298 Review.
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Oncotarget. 2016 Sep 13;7(37):60712-60722. doi: 10.18632/oncotarget.10858. Oncotarget. 2016. PMID: 27474173 Free PMC article. Review.
[Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].Zhonghua Zhong Liu Za Zhi. 2016 Aug;38(8):578-88. doi: 10.3760/cma.j.issn.0253-3766.2016.08.004. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27531477 Chinese.
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.Breast Cancer Res Treat. 2019 Nov;178(2):263-274. doi: 10.1007/s10549-019-05380-z. Epub 2019 Aug 6. Breast Cancer Res Treat. 2019. PMID: 31388935 Free PMC article.